By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
October 21, 2025 11:11 PM EDT
Medical Herald
Search
  • Health Conditions
    Health ConditionsShow More
    New Protein Strategy Offers Hope Against Neurodegenerative Diseases
    Health Conditions
    AI Technology Uses Tongue Color to Predict Health Issues
    Health Conditions
    HealthTap Collaborates with Lilly for Diabetes Care Access
    Diabetes News
    Amanda Balionis Shares Lessons from Health Struggles
    Health Conditions
    Cat’s Crying Leads to Surprising Vet Diagnosis
    Health Conditions
  • Wellness & Self-Care
    Wellness & Self-CareShow More
    Parent Seeks Help After Son Faces Relentless Bullying
    Mental Health
    Embracing a Healthier Lifestyle in Santa Clarita Valley
    Healthy Living
    Managing Anxiety Before Medical Procedures: Alternatives Explored
    Mental Health
    Tomorrow x Together Collaborates with UNICEF on Mental Health
    Mental Health
    Kimchi: A Spicy Superfood for Heart Health With Caution
    Heart Health
  • Nutrition & Fitness
    Nutrition & FitnessShow More
    The Vitamin Over 50s Should Avoid, According to Experts
    Nutrients & Supplements
    Grab Walmart’s Home Gym for $290—Save Over $1,000!
    Fitness Trends & Tech
    Marian Burros’ Iconic Plum Torte Recipe Makes a Timeless Comeback
    Healthy Recipes
    Cozy Fall and Winter Soup Recipes to Savor
    Healthy Recipes
    Doctors Urge Caution on Excessive Supplement Use
    Nutrients & Supplements
  • Innovation
    InnovationShow More
    Sam’s Club Offers Affordable Ozempic, Wegovy for Weight Loss
    Drugs & Medications
    Annual COVID Vaccines Essential for Severe Disease Protection
    Drugs & Medications
    Covid Booster Shots: Are They Necessary for Younger Adults?
    Drugs & Medications
    Exploring Bidirectional Inheritance in Digital DNA Systems
    Innovation
    Amazon Introduces Prescription Kiosks at One Medical Clinics
    Innovation
  • News
    NewsShow More
    Michigan’s Top Children’s Hospital Celebrates 19 Years of Excellence
    News
    SCV Food Pantry Marks 40 Years of Community Service
    News
    J&J Ordered to Pay $966 Million in Talc Baby Powder Case
    News
    New Diagnostic Facility Opens in Oxford to Enhance Cancer Care
    News
    HealthTap Collaborates with Lilly for Diabetes Care Access
    Diabetes News
Font ResizerAa
Medical HeraldMedical Herald
  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
Search
  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
Follow US
Copyright © 2025, Medical Herald. All Rights Reserved.
Home » Health Conditions » Diabetes » Novo Nordisk Resubmits Awiqli Application to FDA

Novo Nordisk Resubmits Awiqli Application to FDA

By Liam Fraser
Published: October 1, 2025
Share

On September 29, 2025, Novo Nordisk A/S announced that it has resubmitted its Biologics License Application (BLA) for Awiqli, a once-weekly basal insulin known scientifically as insulin icodec. This action comes in response to feedback from the U.S. Food and Drug Administration (FDA), following the initial submission.

The resubmission is backed by data gathered from the phase 3 ONWARDS trial, which involved approximately 4,000 adults diagnosed with type 2 diabetes. The ONWARDS trial is a significant clinical study designed to evaluate the efficacy and safety of Awiqli in managing blood sugar levels over an extended period.

If the FDA grants approval, Awiqli is expected to be a significant addition to the treatment landscape for individuals with type 2 diabetes. Daily insulin options can sometimes lead to challenges in adherence, so a weekly regimen may improve patient compliance and ease the overall management of the condition.

Type 2 diabetes affects millions of people worldwide, and finding effective management tools is crucial in combating its prevalence. According to the American Diabetes Association, controlling blood glucose levels is essential for preventing complications associated with diabetes, such as cardiovascular disease, nerve damage, and kidney issues.

Novo Nordisk is a leader in diabetes care, and the introduction of Awiqli could represent a breakthrough in available options for patients. The company has been at the forefront of diabetes innovations and has a portfolio that includes various insulin products and GLP-1 receptor agonists.

In summary, the resubmission of the BLA for Awiqli signifies Novo Nordisk’s dedication to advancing diabetes care. The company’s investment in understanding the needs of patients with type 2 diabetes paired with the latest clinical data from the ONWARDS trial supports the potential impact Awiqli could have in enhancing treatment options. The healthcare community and patients alike are awaiting the FDA’s response to this promising application, which could bring forth a new era in the management of diabetes.

For further updates, stakeholders and interested parties are encouraged to monitor developments surrounding Novo Nordisk and the status of Awiqli, as the quarterly earnings calls and press releases typically provide additional insights into their research and development progress. The market will also be watching how this submission might impact Novo Nordisk’s stock performance, as investor sentiment often aligns closely with new product approvals in the biopharmaceutical industry.

As the landscape of diabetes treatment continues to evolve, Awiqli possesses the potential not only to provide patients with a more convenient administration schedule but also to pave the way for further advancements in diabetes therapies.

To learn more about Novo Nordisk, Awiqli, and other products in their pipeline, you can visit the company’s official website or consult the latest financial filings that reflect their commitment to improving the lives of people living with diabetes.

With the resubmission of this application, Novo Nordisk is reaffirming its role as a trailblazer in the global fight against diabetes, ensuring that innovative solutions are consistently explored to meet the changing needs of patients.Drugs & Medications

TAGGED:FDANovo NordiskType 2 Diabetes
Share This Article
Facebook LinkedIn Email Copy Link
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

HOT NEWS

New Protein Strategy Offers Hope Against Neurodegenerative Diseases

October 21, 2025

The Vitamin Over 50s Should Avoid, According to Experts

Experts warn adults over 50 to avoid excessive Vitamin A and B6 supplements, citing risks…

October 21, 2025

Sam’s Club Offers Affordable Ozempic, Wegovy for Weight Loss

Sam’s Club launches $499 pricing for Ozempic and Wegovy, expanding access to weight-loss meds and…

October 21, 2025

Annual COVID Vaccines Essential for Severe Disease Protection

A new study reveals COVID boosters cut deaths by 64% and hospitalizations by 39%, offering…

October 21, 2025

YOU MAY ALSO LIKE

Novo Nordisk Makes Job Cuts at Major U.S. Plant

Novo Nordisk trims its U.S. workforce amid surging demand for diabetes and obesity drugs, reflecting broader changes in pharmaceutical manufacturing.

October 10, 2025

HealthTap Collaborates with Lilly for Diabetes Care Access

HealthTap’s new partnership with Lilly enhances diabetes management through personalized telehealth care, expanding access to quality treatment nationwide.

October 21, 2025

Transform Your Health: Three Simple Steps to Prevent Diabetes

The PREDIMED-Plus study shows that diet, exercise, and guidance can cut your risk of diabetes by 31%. Here’s how to…

October 2, 2025

Rylee Arnold Shares Journey Managing Diabetes on DWTS

Rylee Arnold reveals how she manages Type 1 diabetes on DWTS—balancing her Dexcom device, diet, and performance demands with honesty…

October 8, 2025

Medical Herald is your trusted source for medical news, scientific research, health policy updates, and expert insights from around the world. 

Category

  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
  • Privacy Policy
  • About Us
  • Contact

Follow US: 

  • Grow Big Agency Sites:
  • London Business Journal
Copyright © 2025, Medical Herald. All Rights Reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?